About MRLV
MRLV is a venture capital firm located in Cambridge, United States. As of Apr 2026, MRLV has invested in 31 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series B round of Ray Therapeutics Overall, MRLV portfolio has seen 9 IPOs and 6 acquisitions including key companies like Spero Therapeutics, Entrada Therapeutics and Xilio Therapeutics. A lot of funds co-invest with MRLV, with names like Solasta Ventures sharing a substantial percentage of its portfolio. MRLV has team of 4 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
MRLV's List of Top Investments
MRLV has a portfolio of 31 companies. Their most notable investments are in Therini Bio and Therini Bio.Their portfolio spans across United States, Netherlands, Australia and 2 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 2 other sectors, across stages such as Series A, Series B and 4 more. Here is the list of top investments by MRLV:Developer of therapeutics for drug-resistant bacterial infections. It offers a portfolio of novel product candidates which includes Tebipenem HBr, an oral carbapenem for pediatric infections, SPR720, an oral antimicrobial agent for the treatment of non-tuberculous mycobacterial lung disease, and SPR206, an intravenous (IV)-administered next-generation polymyxin analog for gram-negative bacterial infections.
Key facts about Spero Therapeutics
- Founded Year: 2013
- Location: Cambridge (United States)
- Annual Revenue: $66.8M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $115M
- Employee Count: 47 as on Mar 31, 2026
- Investors: RA Capital Management, Google Ventures and 16 Others
- Latest Funding Round: Post IPO, Nov 14, 2022, $*****
- Highlight: Public
Developer of the biologics-based platform to treat rare diseases. It has a proprietary intracellular biologics platform which enables intracellular delivery of biologics (proteins, peptides, and nucleic acids). It offers a pipeline of candidates which include ENTR-601-44 Duchenne Muscular Dystrophy, and VX-670 for Myotonic Dystrophy Type 1. It also provide drugs for immunology and ocular indications.
Key facts about Entrada Therapeutics
- Founded Year: 2016
- Location: Boston (United States)
- Annual Revenue: $211M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $175M
- Employee Count: 201 as on Mar 31, 2026
- Investors: Wellington, Goldman Sachs and 11 Others
- Latest Funding Round: Series B, Mar 31, 2021, $*****
- Highlight: Public
Developer of immunotherapies for the treatment of cancer. The company is developing its proprietary technology to create an IO therapy that is activated selectively within the tumor. The product XTX201 (IL-2) induces immune activity in tumors without the toxicity seen with non-selective IL-2s, XTX101, XTX301, and XTX401 demonstrates antitumor activity.
Key facts about Xilio Therapeutics
- Founded Year: 2016
- Location: Waltham (United States)
- Annual Revenue: $43.8M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $233M
- Employee Count: 88 as on Mar 31, 2026
- Investors: RA Capital Management, Deerfield and 16 Others
- Latest Funding Round: Post IPO, Feb 12, 2025, $*****
- Highlight: Public
Developer of radiopharmaceuticals for solid tumor cancers. The company had developed platforms to generate tumor-targeting agents for radiotherapy that are designed for high tumor penetration and long residence time. The therapeutic radioisotope molecules developed eliminates tumors from the body and minimize the side effects.
Key facts about Aktis Oncology
- Founded Year: 2021
- Location: Boston (United States)
- Stage: Public
- Total Funding till date: $336M
- Employee Count: 86 as on Mar 31, 2026
- Investors: RA Capital Management, ArrowMark Partners and 15 Others
- Latest Funding Round: Series B, Sep 20, 2024, $*****
- Highlight: Public
5. Alector
Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders. The drug candidates include AL001 for dementia, AL101 for neurology, AL002, AL003, AL014 for Alzheimer's, and AL008 for oncology. The company has developed antibody drugs that engage key disease-altering and genetically validated neuro-immune targets.
Key facts about Alector
- Founded Year: 2013
- Location: San Francisco (United States)
- Annual Revenue: $21M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $215M
- Employee Count: 162 as on Mar 31, 2026
- Investors: Amgen Business Development, Deerfield and 20 Others
- Latest Funding Round: Series E, Jul 25, 2018, $*****
- Highlight: Public
MRLV's Year-on-Year Investment Trends
MRLV has invested in 31 companies over the last 11 years, with an average of 3 new investments annually in the last 10 years. In 2025, it made 2 investments, while as of Apr 2026, it has made 1 investment in this year. Its most recent first time investment was in ATB Therapeutics and most recent follow-on round was in Ray Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 1 | 1 |
2025 | 0 | 2 | 2 |
2024 | 3 | 1 | 4 |
2023 | 4 | 3 | 7 |
2022 | 3 | 3 | 6 |
2021 | 4 | 4 | 8 |
2020 | 3 | 2 | 5 |
2019 | 3 | 0 | 3 |
2018 | 4 | 1 | 5 |
2017 | 1 | 3 | 4 |
MRLV's Investments by Stage
MRLV is primarily an Early Stage Investor investor majorly investing in Series A (16) rounds where average round size is $1.07B, Series B (5) rounds where average round size is $334M and Seed (4) rounds where average round size is $56.3M.Stage of entry | No. of Investments |
|---|---|
Series A | 16 |
Series B | 5 |
Seed | 4 |
Post IPO | 2 |
Series C | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
MRLV's Investments by Sector
MRLV has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Enterprise Applications and HealthTech. Notably, it has invested in 29 Enterprise (B2B) companies, 29 Tech companies, 2 Software companies and 1 company focusing on Social impact.Sector | No. of Investments |
|---|---|
Life Sciences | 27 |
High Tech | 5 |
Sustainability Tech | 3 |
Enterprise Applications | 2 |
HealthTech | 2 |
Others | 2 |
Note: We have considered here, only first round of investments
MRLV's Investments by Geography
MRLV has made most investments in United States (24), followed by Netherlands where it has made 3 investments.Country | No. of Investments |
|---|---|
United States | 24 |
Netherlands | 3 |
Australia | 1 |
Belgium | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
MRLV's recent investments
MRLV has made 1 investments in 2026 so far - Ray Therapeutics.Here are the most recent investments by MRLV:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 21, 2026 | United States | Series B | 4576 | ||
May 14, 2025 | United States | Series A | 2661 | [+7] | |
May 06, 2025 | United States | Series B | 7309 | [+4] | |
Nov 18, 2024 | Belgium | Series A | 7966 | [+5] | |
Oct 18, 2024 | United States | Series A | 7200 |
IPOs and Publicly Listed companies in MRLV's Portfolio
9 of MRLV's portfolio companies have become public. Aktis Oncology got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jan 2026 at marketcap of $945M and Entrada Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $598M.Here are MRLV's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jan 09, 2026 | Aug 25, 2022 | Series A | 9800 | |
Oct 29, 2021 | Dec 22, 2018 | Series A | 1140 | |
Oct 22, 2021 | Mar 02, 2020 | Series B | 6549 | |
Aug 21, 2020 | Nov 13, 2018 | Series B | 8450 | |
Feb 07, 2019 | Jan 07, 2016 | Series D | 4408 |
Acquired companies in MRLV's Portfolio
6 companies from MRLV's portfolio have been acquired. The most recent acquisition were LAVA therapeutics in Aug 2025 by XOMA Corporation.Here are MRLV's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 04, 2025 | May 23, 2018 | Series A | 7201 | |
May 29, 2024 | Feb 22, 2022 | Series A | 8454 | |
Nov 21, 2023 | Nov 26, 2018 | Series A | 2104 | |
Nov 21, 2022 | Mar 20, 2019 | Series B | 4896 | |
Aug 03, 2021 | Jul 23, 2015 | Series B | 3427 |
_1582604151324.jpeg?devicePixelRatio=2&height=20&width=20){kind=logo}
Team profile of MRLV
MRLV has a team of 4 members including 3 Partners located in United States. MRLV's team does not sit on the board of any company as of now.Here is a list of all team members in MRLV:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Cambridge | - | - | |
Partner | Cambridge | - | - | |
Partner | Cambridge | - | - |
Co-investors of MRLV
Over the past 11 years, 268 investors have co-invested in MRLV's portfolio companies. This includes funds and angels.
- Invested before MRLV: Atlas Venture, Amgen Business Development and 51 others have invested in rounds before MRLV. There are 6 companies where Atlas Venture has invested before MRLV and 3 companies where Amgen Business Development has invested before MRLV.
- Top Co-investors of MRLV: 121 investors entered a company along with MRLV. These include investors like Solasta Ventures (3 companies).
- Invested after MRLV: A total of 94 investors have invested in MRLV's portfolio after their investments. Top Investors include RA Capital Management (3 companies), Rock Springs Capital (3 companies) and HHS (3 companies).
Recent News related to MRLV
•
Therini Bio Secures $39 Million in Series A Funding for Neurodegenerative Disease PipelineJinglingshuju•May 15, 2025•Therini Bio, Sanofi Ventures, MRLV, Better World Foundation and 5 others
•
Baker McKenzie advises ATB Therapeutics on 54 million euros Series A financingRecht•Dec 02, 2024•Baker McKenzie, ATB Therapeutics, EQT, V-Bio Ventures and 5 others
•
Axonis Therapeutics: $115 Million (Series A) Raised To Develop Novel NeuromedicinesPulse 2.0•Nov 08, 2024•AXONIS Therapeutics, Sofinnova Investments, MRLV, Perceptive Advisors and 19 others
•
Axonis snags $115M to test oral drugs for epilepsy and neuropathic painEndPoints News•Oct 30, 2024•AXONIS Therapeutics, Cormorant Asset Management, VenBio, Sofinnova Investments and 6 others
•
Radiopharma biotech Aktis sees Big Pharma backers return for $175M series BFierce Biotech•Sep 30, 2024•Aktis Oncology, Bristol-Myers Squibb, MRLV, RA Capital Management and 5 others
•
•
Insamo Launches with $12M Funding from Playground Global, venBio, and MRL Ventures Fund to Develop Best-in-Class Membrane-Permeable Macrocyclic PeptidesBusiness Wire•Feb 21, 2024•Insamo, Playground, VenBio, MRLV and 5 others
•
EyeBio Expands Series A to $130MFinSMEs•Nov 14, 2023•EyeBio, Bain Capital Life Sciences, Omega Funds, Vertex Ventures HC and 2 others
•
Amsterdam’s VectorY Therapeutics closes one of Europe’s largest private biotech financings in 2023Silicon Canals•Nov 14, 2023•VectoryTx, Forbion, MRLV, Merck and 4 others
•
VectorY Raises €129 Million ($138 Million) Series A Financing to Advance Vectorized Antibody Programs in Neurodegenerative DiseasesBusiness Wire•Nov 13, 2023•VectoryTx, EQT, MRLV, Insight Partners and 4 others
